Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>Resources>White Papers>This White Paper
  White Papers
Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
New Therapeutic Target for Crohn’s Disease
A promising new target for drugs that treat IBD has been identified along with a possible biomarker for IBD severity.
Researchers Find Fungus-Fighting Compound
A compound has been identifed that blocks growth of a fungus responsible for lung infections and allergic reactions.
Analysing 10,000 Cells Simultaneously
New techniquethat traps 10,000 cells on a single chip has potential for cancer screening for individuals.
Peer Reviewed Study Demonstrates Mass Spec Technique
The peer reviewed study demonstrates MS workflow, TMTCalibrator workflow, which dramatically enhances detection of key early stage Alzheimer’s biomarkers.
Small Molecules Lead to a Big Change in Reaction Outcomes
Scientists have changed the behaviour of a group of molecules involved in carbon-oxygen bond synthesis.
Enhancing Antibiotics to Defeat Resistant Bacteria
Scientists enhance ability of antibiotics to defeat resistant types of bacteria using molecules called PPMOs
Sanger Institute, St Jude Data-Sharing Agreement
Childhood cancer targeted by Sanger Institute and St Jude Children’s Research Hospital exchanges of cancer data
Over Two-Thirds of Cervical Cancer Deaths Prevented
Cervical screening prevents 70% of cervical cancer deaths and if all eligible women regularly attended screening this would rise to 83%.
Scroll Up
Scroll Down

Dawn of a New Era for Kinase Drug Discovery: Kinome Wide Profiling and Screening Solutions Coupled to Functional Cell-based Assays Enable Launch of Selective and Functional Kinase Inhibitors
Bookmark and Share

DiscoveRx Corporation

It is no mystery that the global drug discovery market is continuously under pressure to perform against rapidly shifting regulations, timelines and performance data while balancing meaningful innovation and profitability. The industry is rising to the challenge as innovative new drug discovery technologies are fueling continuous improvements across the effectiveness of marketed drugs while minimizing potential adverse side effects. This is where novel product and service portfolios from companies like DiscoveRx® play a pivotal role in offering a range of GPCR and Kinase based tools that give their customers the power to discover new drugs.

Further Information

Related Content

Validation of Drug Toxicity Prediction using DiscoveRx Model
BioMAP® Systems was shown to identify important safety aspects of drugs and chemicals more efficiently and accurately than can be achieved by animal testing.
Tuesday, May 20, 2014
DiscoveRx Corporation Continues to Innovate with Solutions for Epigenetic Drug Discovery Programs
The company announced availability of platform for studying Bromodomains, an emerging class of epigenetic targets.
Monday, February 06, 2012
DiscoveRx Expands its GPCR Technology Portfolio to Include Advanced Technologies
Introduces two additional GPCR platforms to facilitate counterscreening, lead optimization and SAR evaluation of compounds.
Friday, April 09, 2010
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!